Yasuaki Ogawa

TL;DR: Investigation of biological properties of an immune complex of recombinant interleukin-2 (rIL-2) and a monoclonal antibody against ril-2 in mice for induction of killer cells and for anti-tumor activity indicates that immunocomplexing of r IL-2 with an antibody against the immune complex provides a useful tool as the drug delivery system for cancer therapy using rIL- 2.

TL;DR: The results indicate that the LUV is more favourable than the SUV for thermosensitive delivery with respect to arug encapsulation capacity, liposome stability and drug release and that the osmotic pressure of the internal aqueous space should be 1.5 or more times as high as the physiological osmosis pressure for heat-specific drug release.

TL;DR: Injectable microcapsules of 30 micrometer in mean diameter were prepared in order to release TAK-778 over 4 weeks using a biodegradable polymer, poly(d,l-lactic/glycolic) acid, with a copolymer ratio of 85:15 (mol/mol) and an average molecular weight of 14,000.

TL;DR: These results confirm earlier findings that LUV-1 andLUV-2 release CDDP almost completely at the heated tumor and that the large DTI value obtained in L UV-1 (DTI = 4.6) was due to its high heat sensitivity and its small systemic clearance.

TL;DR: The results indicate that the tumor-CDDP level increase after thermosensitive liposome administration is due to CDDP release from the liposomes in the blood at or adjacent to the heated tumor, and LUV, such as LUV-1, exhibit higher heat sensitivity and larger, targeted drug delivery efficiency than SUV.